These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17200293)

  • 1. Give Synagis via home health.
    Goldenring J
    Pediatrics; 2007 Jan; 119(1):219. PubMed ID: 17200293
    [No Abstract]   [Full Text] [Related]  

  • 2. Give Synagis via home care: a reply.
    Schipper JA
    Pediatrics; 2007 Jun; 119(6):1258-9; author reply 1259. PubMed ID: 17545406
    [No Abstract]   [Full Text] [Related]  

  • 3. Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab.
    Meissner HC; Anderson LJ; Pickering LK
    Pediatrics; 2004 Oct; 114(4):1082-4. PubMed ID: 15466107
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing RSV in pediatric patients: improving the outcome at home.
    Borell M; Myers J; Rineair S
    Caring; 2007 Sep; 26(9):34-7. PubMed ID: 17948847
    [No Abstract]   [Full Text] [Related]  

  • 5. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.
    Hand IL; Noble L; Geiss D; Shotkin A
    Pediatr Infect Dis J; 2008 Feb; 27(2):175-6. PubMed ID: 18174866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prophylaxis against RS virus infection].
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Lakartidningen; 2002 Jan; 99(3):170-1. PubMed ID: 11838073
    [No Abstract]   [Full Text] [Related]  

  • 9. [Polivizumab against respiratory syncytial virus?].
    Brunvand L
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2570-2. PubMed ID: 11070999
    [No Abstract]   [Full Text] [Related]  

  • 10. [Infections with RS viruses in children].
    Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393
    [No Abstract]   [Full Text] [Related]  

  • 11. A health care management company's experience with palivizumab.
    Silverman W
    Manag Care; 2002 Jan; 11(1):45-6. PubMed ID: 11828875
    [No Abstract]   [Full Text] [Related]  

  • 12. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
    Rodríguez SP; Fariña D; Bauer G
    Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health plan pharmacy director: considerations for treatment and management of RSV disease.
    Burgoyne DS
    Manag Care; 2008 Nov; 17(11 Suppl 12):17-8, discussion 18-9. PubMed ID: 19102025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
    Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
    Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors impacting compliance with palivizumab prophylaxis.
    Pignotti MS; Indolfi G; Donzelli G
    Pediatr Infect Dis J; 2004 Feb; 23(2):186-7. PubMed ID: 14872196
    [No Abstract]   [Full Text] [Related]  

  • 17. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. North American synagis prophylaxis survey.
    Giusti R
    Pediatr Pulmonol; 2009 Jan; 44(1):96-8. PubMed ID: 19085922
    [No Abstract]   [Full Text] [Related]  

  • 19. The cost and safety of multidose use of palivizumab vials.
    Gooding J; Millage A; Rye AK; Lacroix R
    Clin Pediatr (Phila); 2008 Mar; 47(2):160-3. PubMed ID: 17901213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Main results of a national multicenter study assessing the compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection.
    Macagno F;
    Pediatr Med Chir; 2005; 27(3-4):70-7. PubMed ID: 16910454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.